Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology and Therapeutics
• Antimicrobial Stewardship

Background:

• Amoxicillin-clavulanate (A/C) is a primary treatment for acute otitis media (AOM) in children.
• Standard A/C dosage frequently causes diarrhea, impacting treatment adherence.
• Exploring lower clavulanate concentrations may mitigate side effects while maintaining efficacy.

Purpose of the Study:

• To evaluate if a reduced-clavulanate A/C formulation decreases diarrhea incidence in children with AOM.
• To assess if lower clavulanate dosages maintain adequate plasma levels for pathogen eradication.
• To compare clinical success rates and side effects between standard and reduced-clavulanate A/C regimens.

Main Methods:

• An open-label study involving children aged 6-23 months with AOM.
• Phase 1: 40 children received 90 mg amoxicillin/3.2 mg clavulanate/kg/day.
• Phase 2: 72 children received 80 mg amoxicillin/2.85 mg clavulanate/kg/day; outcomes compared to historical standard-dose A/C data.

Main Results:

• Reduced clavulanate dosages showed comparable clinical efficacy to standard A/C.
• Phase 2 regimen showed a trend towards lower rates of protocol-defined diarrhea (17% vs. 26%) and significantly lower diaper dermatitis (21% vs. 33%).
• Plasma levels of both amoxicillin and clavulanate remained sufficient to inhibit beta-lactamase activity.

Conclusions:

• Lower clavulanate dosages in A/C formulations may reduce gastrointestinal side effects in young children with AOM.
• Reduced-dose A/C appears to be a viable alternative for AOM treatment, improving tolerability.
• Further research could optimize A/C dosing for pediatric otitis media to enhance patient outcomes and adherence.